Importance Obesity affects approximately 19% of women and 14% of men worldwide and is
associated with increased morbidity. Antiobesity medications (AOMs) modify biological …

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Obesity has increased in prevalence worldwide and WHO has declared it a global epidemic.
Population-level preventive interventions have been insufficient to slow down this trajectory …

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

Diabetes, a complex multisystem metabolic disorder characterized by hyperglycemia, leads
to complications that reduce quality of life and increase mortality. Diabetes pathophysiology …

Abstract 'Westernization', which incorporates industrial, cultural and dietary trends, has
paralleled the rise of noncommunicable diseases across the globe. Today, the Western-style …

Background Recently, many drugs have been approved for halting overweight and obesity—
few types of research shifted to using Anti-obesity medications (AOM) solely for well-being …

The history of anti-obesity pharmacotherapies is marked by disappointments, often
entangled with societal pressure promoting weight loss and the prevailing conviction that …